ONL’s team is comprised of experienced and successful life science industry executives and world-renowned thought-leaders in relevant fields of ocular disease research.
PRESIDENT AND CHIEF EXECUTIVE OFFICER
David Esposito is an experienced healthcare executive who has built and scaled multiple companies that resulted in successful exits to strategic buyers.
David is the former CEO of Armune BioScience where he led the development and commercialization of blood-based diagnostics to improve the early detection of cancer. The Company successfully launched the only non-PSA blood test to improve the detection of prostate cancer. Armune BioScience was sold to Exact Sciences (EXAS) in 2017.
He was President of Phadia US Inc. (allergy and autoimmune diagnostics) and played a pivotal role in the sale of the business to Thermo Fisher Scientific (TMO) for in 2011. David began his career as a sales representative with Merck & Co. Inc. and rose through the ranks of sales, marketing and commercial strategy for the US Division.
David is a combat veteran, led an infantry platoon with the 101st Airborne Division through several combat operations, and was recognized with a Bronze Star for combat action in Iraq in 1991. David earned his B.S. degree in Civil Engineering from the United States Military Academy at West Point and his MBA from Syracuse University.
David Zacks, M.D., Ph.D.
CO-FOUNDER AND CHIEF SCIENCE OFFICER
Dr. Zacks is a professor of ophthalmology and a clinician-scientist at the University of Michigan, Kellogg Eye Center. For over the past 15 years his research has focused on the molecular regulatory mechanisms controlling photoreceptor death or survival in retinal disease. Dr. Zacks is a pioneer and recognized thought leader in the field of retinal neuroprotection and photoreceptor cells physiology. He has demonstrated that the Fas pathway is largely responsible for cell death and has discovered unique molecules that block the Fas receptor and preserve photoreceptors.
A recognized expert in the study of retinal detachment, Dr. Zacks has received numerous honors for his work, including the Macula Society’s W. Richard Green Lecture and Award in 2011. He earned his M.D. and Ph.D. degrees at Albert Einstein College of Medicine and completed his residency in ophthalmology and fellowship in vitreoretinal surgery at Massachusetts Eye and Ear Infirmary of Harvard Medical School.
Connie brings a diverse 25-year career in life science and business to ONL, having worked in large and small pharma, early-stage biomedical technology commercialization and management consulting. Previously, she served as Vice President of Corporate Affairs at Millendo Therapeutics where she was responsible for building critical infrastructure as the company became publicly traded, including investor and public relations, corporate communications, and facilities/operations. Connie was managing director of Fast Forward Medical Innovation (FFMI), the commercialization and entrepreneurship arm of the University of Michigan Medical School, supporting early-stage technology development. At Sepracor (now Sunovion) Connie was Senior Director and brand team leader for the sedative hypnotic and respiratory franchises, developing integrated marketing plans and sales force strategies, including the launch of product line extensions. Earlier in her career, Connie worked at Pfizer on commercial teams in allergy/respiratory, cardiovascular and CNS.
Connie received her Bachelor of Arts degree in psychobiology from Harvard University, graduating magna cum laude and Phi Beta Kappa, and an MBA from Harvard Business School.
Sushanta Mallick, PhD, MBA
Dr. Mallick brings 30 years of experience in ophthalmology research and development, with over a decade in senior leadership roles in companies spanning the US, Canada, and Europe. Prior to joining ONL, Dr. Mallick was the Vice President and Head of Clinical Development at Nicox Ophthalmics, an international ophthalmology company headquartered in Nice, France, where he led the development program for two ongoing Phase 3 clinical trials in the US and China for its lead compound in glaucoma. Dr. Mallick gained his therapeutic area expertise in ophthalmology at Alcon Research Ltd. in Ft. Worth, Texas, where he held positions of increasing responsibilities that resulted in four product approvals in glaucoma and culminated in an appointment with Alcon’s ESBATech, a biomedical research company based in Zurich, Switzerland. As the clinical unit head there, he directed two IND submissions and proof of concept trials resulting in the market approval for a new wet AMD product. As Vice President of R&D at QLT Inc. in Vancouver, he led the development of an oral synthetic retinoid as an orphan drug in inherited retinal diseases. Previously, as Vice President and Global Development Lead at Shire/Takeda, he managed all aspects of multiple ophthalmic development programs, from late preclinical stages through commercialization. Dr. Mallick has a MPharm in Pharmaceutics, PhD in Biochemistry and MBA in Marketing and International Management.
Andrew Kocab, Ph.D.
SENIOR DIRECTOR, RESEARCH AND STRATEGIC PARTNERSHIPS
Dr. Kocab earned his Ph.D. in immunology at the University of Michigan where he studied cell signaling pathways related to cell death and inflammation. Specifically, his work focused on understanding the signaling from receptors closely related to Fas, as well as the effector proteins involved in regulating these processes.
During his time at ONL, Dr. Kocab has worked closely with senior management on a variety of key functions across the company. He currently leads the company’s research, preclinical, and data management activities. In his role, Dr. Kocab also serves as the company’s primary liaison with critical strategic partners and collaborators.
Lindsay Godsey, MS, COA, CCRP
Lindsay Godsey is an experienced clinical research professional with a specialized background in ophthalmologic clinical trials.
Lindsay formerly served as Clinical Research Project Manager for the Kellogg Eye Center at the University of Michigan, the nation’s largest public research university. Over her ten years there she oversaw a portfolio of over 200 clinical studies ranging from phase 0 to post-market approval, with a focus in inherited retinal dystrophy pediatric gene therapy trials. Lindsay managed a nine-person team to execute every aspect of the clinical trial process, including protocol and study development, regulatory compliance and risk mitigation, subject recruitment and retention, as well as safety and data management.
Previously, Lindsay worked as an emergency medical technician and a rehabilitation specialist for adults with brain and spinal cord injuries. A Certified Clinical Research Professional and Ophthalmic Assistant, Lindsay earned her B.S. in Nutritional Sciences from Michigan State university and M.S. in Nutrition and Food Science from Wayne State University.
Manager of Accounting and Financial Reporting
Since joining ONL in 2021, Amanda has been responsible for developing an in-house capability for accounting and financial reporting, a key area for the company’s future growth and success. Amanda most recently was senior accountant with Millendo Therapeutics, a publicly-traded, early-stage biopharma company where she managed internal accounting and finance processes, in addition to leading special projects for the implementation of enterprise-wide financial administration systems. Amanda has a background in corporate accounting from the technology manufacturing sector in addition to her degree in Management Science from University of California, San Diego.
Manager, Administrative Operations
Linda has nearly 25 years of experience providing operations and administrative support across a broad range of companies, from large CROs to small biotech. Linda joined ONL in 2018 where, in her role as Manager, Administrative Operations, she helps behind the scenes with multiple functions related to company operations including financial management, information technology/cybersecurity and HR.